Dr. Yu has enjoyed a successful career as an innovator in life sciences, engineering and technology.
Worked for three U.S. Fortune 500 companies.
First or principal Inventor of over 300 patent applications spanning semiconductor, materials and life science.
Proven history developing cutting-edge products with long-term profit and sustainability.
Received his bachelor and master’s degrees in physics from the University of Missouri Kansus-City Campus, and a doctoral degree in physics from the Pennsylvania State University. His master’s and doctoral dissertations both addressed innovative detection techniques.
Renowned expert in a molecular epidemiologist, with training in medicine, epidemiology, and clinical biochemistry.
20 year career in leading-edge cancer research including, breakthrough work in the areas of carcinogenic factors & molecular epidemiology.
Professor & Research Director at University of Hawaii & Adjunct Professor at Yale University.
Received his doctor’s degree in medicine from Shanghai First Medical College in 1983. He also received a master of science degree in epidemiology and a PhD in clinical biochemistry from University of Toronto in 1990 and 1996, respectively.
Served as a general partner at Stirrfir Investment Management Co., Chairman of RTS Management (Shanghai) Co., and Managing director of Hong Kong Pro-Health Technology Co., and Shanghai Pro-Health Medical Devices Co.
Was Chief Scientific Officer at Wex International Inc. (a subsidiary of a U.S. listed company) and an adjunct professor at Anhui College of Traditional Chinese Medicine.
Has published a number of medical research papers and scientific articles in professional journals and was awarded the Hong Kong Industrial Award for a medical device that he led in research and development.
Received his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.
Served as a general manager-operation at Buckman Laboratories (Asia) Pte. Ltd. (Singapore) and finance director at Buckman Laboratories Shanghai Chemicals Co., Ltd.
She is a Chartered Global Management Accountant (CGMA) and Certified Public Accountant.
Received bachelor’s degree in accounting from Shanghai University of Finance and Economics and master’s degree in business administration from AnTai College of Economics & Management, Shanghai Jiao Tong University.
Early cancer screening saves lives and dramatically reduces costs.
Cancer types detected
Individuals screened out & identified with an early stage of disease
Sensitivity & specificity for most cancer types
General population screening & clinical research samples
Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.